Cardiovascular disease: Strategies for risk assessment and modification

Journal of Cardiovascular Nursing

Volumn 21, Issue 6 SUPPL.1, 2006, Pages

  Braun, Lynne T ^a  

^a RUSH UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Diabetes; Homocysteine; Hypertension; Inflammatory factors; Lipids; Lipoprotein (a); Obesity; Smoking

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOFIBRIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASE; COMORBIDITY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; LIFESTYLE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; PREDICTION AND FORECASTING; PREVALENCE; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; UNITED STATES;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INCIDENCE; LIFE STYLE; LIPOPROTEIN(A); MALE; MIDDLE AGED; OBESITY; PRACTICE GUIDELINES; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SMOKING; UNITED STATES;

EID: 33846973048     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200611001-00004     Document Type: Review

References (157)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
2. Centers for Disease Control. Division for Heart Disease and Stroke Prevention: 2006. Available at: http://www.cdc.gov/nccdphp/publications/aag/cvh. htm. Accessed May 17, 2006.
3. Cohn PF. Silent myocardial ischemia: recent developments. Curr Atheroscler Rep. 2005;7:155-163.
4. American Heart Association, American Stroke Association. Heart Disease and Stroke Statistics-2006 Update At-a-Glance. Available at: http://www.americanheart.org/ statistics/biostats/index.htlm. Accessed May 15, 2006.
5. Fleg JL, Gerstenblith G, Zonderman AB, et al. Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. Circulation. 1990;81:428-436.
6. Froelicher VF, Thompson AJ, Longo MR Jr, et al. Value of exercise testing for screening asymptomatic men for latent coronary artery disease. Prog Cardiovasc Dis. 1976;16:265-276.
7. Thaulow E, Erikssen J, Sandvik L, Etikssen G, Jorgensen L, Cohn PF. Initial clinical presentation of cardiac disease in asymptomatic men with silent myocardial ischemia and angiographically documented coronary artery disease (the Oslo Ischemia Study). Am J Cardiol. 1993;72:629-633.
8. He Z-X, Hedrick TD, Pratt CM, et al. Severity of coronary artery calcification by electron beam computed tomography predicts silent myocardial ischemia. Circulation. 2000;101:244-251.
9. Ilić SN, Ilić MZD, Lović BK, et al. Prevalence, characteristics and three years prognostic significance of silent myocardial ischemia during early exercise testing in patients after the first myocardial infarction. Med Biol. 2000;5:56-61.
10. Deedwania PC, Carbajal EV. Prevalence and patterns of silent myocardial ischemia during daily life in stable angina patients receiving conventional antianginal drug therapy. Am J Cardiol. 1990;65:1090-1096.
11. Wackers FJTh, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects. Diabetes Care. 2004;27:1954-1961.
12. Valensi P, Pariès J, Brulport-Cerisier V, et al. Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study. Diabetes Care. 2005;28:2722-2727.
13. Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V. Silent myocardial ischemia in patients with diabetes. Diabetes Care. 1999;22:1396-1400.
14. Koistinen MJ. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects. BMJ. 1990;301:92-95.
15. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am J Cardiol. 1997;79:134-139.
16. Valensi P, Sachs RN, Lormeau B, et al. Silent myocardial ischaemia and left ventricle hypertrophy in diabetic patients. Diabetes Metab. 1997;23:409-416.
17. Conlon PJ, Krucoff MW, Schumm MS, Schwab SJ. Incidence and long-term significance of transient ST segment deviation in hemodialysis patients. Clin Nephrol. 1998;49:236-239.
18. Raby KE, Goldman L, Cook EF, et al. Long-term prognosis of myocardial ischemia detected by Holter monitoring in peripheral vascular disease. Am J Cardiol. 1990;66:1309-1313.
19. Vlachopoulos C, Rokkas K, Ioakeimidis N, et al. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study. Eur Urol. 2005;48:996-1002.
20. Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation. 2004;110:22-26.
21. Mosca L, Ferris A, Fabunmi R, Robertson RM. Tracking women's awareness of heart disease. An American Heart Association national study. Circulation. 2004;109:573-579.
22. Mosca L, Mochari H, Christian A, et al. National study of women's awareness, preventive action, and barriers to cardiovascular health. Circulation. 2006;113:525-534.
23. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction. J Am Coll Cardiol. 1998;32:140-146.
24. Goldberg RJ, O'Donnell C, Yarzebski J, Bigelow C, Savageau J, Gore JM. Sex differences in symptom presentation associated with acute myocardial infarction: a population-based perspective. Am Heart J. 1998;136:189-195.
25. Shaw LJ, Miller DD, Romeis JC, Kargl D, Younis LT, Chaitman BR. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. Ann Intern Med. 1994;120:559-566.
26. Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD, for the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. Sex bias and underutilization of lipidlowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Arch Intern Med. 2000;160:343-347.
27. Mosca L, Merz NB, Blumenthal RS, et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation. 2005;111:488-493.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
29. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
30. Michos ED, Nasir K, Braunstein JB, et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis. 2006;184:201-206.
31. Michos ED, Vasamreddy D, Becker L, et al. Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. Am Heart J. 2005;150:1276-1281.
32. Nasir K, Michos ED, Rumberger JA, et al. Coronary artery calcification and family history of premature coronary heart disease: sibling history is more strongly associated than parental history. Circulation. 2004;110:2150-2156.
33. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-798.
34. Kostner G, Krempler F. Lipoprotein(a). Curr Opin Lipidol. 1992;3:279-284.
35. Sorensen KE, Celermajer DS, Georgakopoulos D, et al. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest. 1994;93:50-55.
36. Hunninghake DB, Stein EA, Mellies MJ. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein(a). J Clin Pharmacol. 1993;33:574-580.
37. Cressman MD, Heyka RJ, Paganini EP, et al. Lipoprotein( a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 1992;86:475-482.
38. Wanner C, Rader D, Bartens W, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med. 1993;119:263-269.
39. Genest JJ, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-1 and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792-802.
40. Jurgens G, Koltringer P. Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurology. 1987;37:513-515.
41. Murai A, Miyahara T, Fujimoto N, et al. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59:199-204.
42. Valentine RJ, Grayburn PA, Vega GL, et al. Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med. 1994;154:801-806.
43. Desmarais RL, Sarembock IJ, Ayers CR, et al. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after balloon coronary angioplasty. Circulation. 1995;91:1403-1409.
44. Terres W, Tatsis E, Pfalzer B, et al. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation. 1995;91:948-950.
45. Genest JJ, Jenner JL, McNamara JR, et al. Prevalence of lipoprotein(a) excess in coronary artery disease. Am J Cardiol. 1991;67:1039-1045.
46. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA. 1996;276:544-548.
47. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-2199.
48. Ariyo AA, Thach C, Tracy R, et al. Lp(a) lipoprotein, vascular disease and mortality in the elderly. N Engl J Med. 2003;349:2108-2115.
49. Maher VMG, Brown BG, Marcovina SM, Hillger LA, Zhao X-Q, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA. 1995;274:1771-1774.
50. Dinavahi R, Falkner B. Relationship of homocysteine with cardiovascular disease and blood pressure. J Clin Hypertens. 2004;6:494-498.
51. Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep. 2006;8:100-106.
52. Arnesen E, Refsum H, Bønna KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704-709.
53. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a metaanalysis. JAMA. 2002;288:2015-2022.
54. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
55. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-1588.
56. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350:2673-2681.
57. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
58. Koenig W, Lowel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in Southern Germany. Circulation. 2004;109:1349-1352.
59. Ridker PM, Rifai N, Rose L, et al. Comparison of Creactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
60. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
61. 2 adds to risk prediction of incidence coronary events by C-reactive protein in apparently healthy middle-aged men from the general population. Results from the 14-year follow-up of a large cohort from Southern Germany. Circulation. 2004;110:1903-1908.
62. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001;104:1863-1867.
63. Anthony D. Diagnosis and screening of coronary artery disease. Prim Care Clin Office Pract. 2005;32:931-946.
64. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720-732.
65. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
66. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
67. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
68. Sacks RM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
69. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
70. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
71. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
72. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
73. De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservation simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. JAMA. 2004;292:1307-1316.
74. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
75. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. Results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46:1405-1410.
76. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid. lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
77. Pedersen TR, Faergeman O, Kastelein JJP, et al. Highdose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.
78. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
79. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA. 2004;291:1071-1080.
80. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA. 2006;295:1556-1565.
81. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 1997;17:107-113.
82. Gordon DJ, Rifkind BM. High-density lipoproteinVthe clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
83. Pekkanen J, Linj S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700-1707.
84. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 1991;67:1185-1189.
85. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol. 1995;75:1196-1201.
86. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
87. Laakso M, Voutilainen E, Sarlund H, et al. Serum lipids and lipoproteins in middle aged non-insulin dependent diabetics. Athersoclerosis. 1985;56:271-281.
88. Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes. Arterioscler Thromb. 1992;12:1496-1502.
89. Wilson PWF, Kannel WB, Anderson KM. Lipids, glucose intolerance and vascular disease: the Framingham study. Monogr Atheroscler. 1985;13:1-11.
90. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005;366:1849-1861.
91. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-2572.
92. Niskanen L, Laaksonen DE, Nyyssoönen K, et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension. 2004;44:859-865.
93. Stranges S, Wu T, Dorn JM, et al. Relationship of alcohol drinking pattern to risk of hypertension. A population-based study. Hypertension. 2004;44:813-819.
94. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
95. Wang W, Lee ET, Fabsitz RR, et al. A longitudinal study of hypertension risk factors and their relation to cardiovascular disease. Hypertension. 2006;47:403-409.
96. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regiments on major cardiovascular events: result of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1534.
97. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
98. Poulter NR, Wedel H, Dahlof B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:907-913.
99. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patient who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcome Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
100. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care. 2004; 27(suppl 1):S65-S67.
101. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918.
102. Cho E, Manson JE, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease among diabetic women. Diabetes Care. 2002;25:1142-1148.
103. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
104. Yusuf S, Vaz M, Pais P. Tackling the challenge of cardiovascular disease burden in developing countries. Am Heart J. 2004;148:1-4.
105. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women. Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes. 1996;45:633-638.
106. National Heart, Lung, and Blood Institute in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH Publication no. 98-4083. September 1998.
107. Haffner SM, Lehto S, Roönnemaa T, Pyoöraölaö K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:220-234.
108. Curb JD, Pressel SL, Cutler JA, et al. Effect of diureticbased antihypertensive treatment of cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886-1892.
109. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
110. Tuomilehto J, Rastenyte D, Birkenhaöger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
111. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-720.
112. Parving H-H, Lehnert H, Broöchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
113. Lewis EJ, Hansicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
114. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
115. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
116. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-1250.
117. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
118. Kannel WB. Update on the role of smoking in coronary artery disease. Am Heart J. 1981;101:319-328.
119. Stamler J. Cigarette smoking and atherosclerotic coronary artery disease. Bull N Y Acad Med. 1968;44:1476-1494.
120. Cullen P, Schulte H, Assmann G. Smoking, lipoproteins and coronary heart disease risk. Data from the Muönster Heart Study (PROCAM). Eur Heart J. 1998;19:1632-1641.
121. Freeman DJ, Packard CJ. Smoking and plasma lipoprotein metabolism. Clin Sci. 1995;89:333-342.
122. Eliasson M, Lundblad D, Haögg E. Cardiovascular risk factors in young snuff-users and cigarette smokers. J Intern Med. 1991;230:17-22.
123. Midgette AS, Baron JA, Rohan TE. Do cigarette smokers have diets that increase their risks of coronary heart-disease and cancer? Am J Epidemiol. 1993;137:521-529.
124. Nuttens MC, Romon M, Ruyidavets JB, et al. Relationship between smoking and diet: the MONICA-France project. J Intern Med. 1992;231:349-356.
125. U.S. Department of health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General-Executive Summary. U.S. Department of Helath and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2006.
126. Moffat RJ. Effects of cessation of smoking on serum lipids and high density lipoprotein-cholesterol. Atherosclerosis. 1988;74:85-89.
127. Centers for Disease Control and Prevention (CDC). State-specific prevalence of cigarette smoking and quitting among adults-United States, 2004. MMWR Morb Mortal Wkly Rep. 2005;54:1124-1127.
128. Prochazka AV. New developments in smoking cessation. Chest. 2000;117(suppl):169S-175S.
129. Mallin R. Smoking cessation: integration of behavioral and drug therapies. Am Fam Physician. 2002;65:1107-1114, 1117.
130. Warburton DER, Nicol CW, Bredin SSD. Health benefits of physical activity: the evidence. CMAJ. 2006;174:801-809.
131. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372.
132. Scrutinio D, Bellotto F, Lagioia R, Passantino A. Physical activity for coronary heart disease: cardioprotective mechanisms and effects on prognosis. Monaldi Arch Chest Dis. 2005;64:77-87.
133. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systemic review and meta-analysis of randomized controlled trials. Am J Med. 2004;226:682-692.
134. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA. 1995;273:402-407.
135. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. A statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003;107:3109-3116.
136. Swain DP, Franklin BA. Comparison of cardioprotective benefits of vigorous versus moderate intensity aerobic exercise. Am J Cardiol. 2006;97:141-147.
137. Warburton DER, Nicol CW, Bredin SSD. Prescribing exercise as preventive therapy. CMAJ. 2006;174:961-974.
138. American College of Sports Medicine. Position stand: the recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness and flexibility in healthy adults. Med Sci Sports Exerc. 1998;30:975-991.
139. Briffa TG, Maiorana A, Sheerin NJ, et al. Physical activity for people with cardiovascular disease: recommendations of the National Heart Foundation of Australia. Med J Aust. 2006;184:71-75.
140. Seniorjournal.com. Medicare expands service for cardiac rehab, cancer detection, home oxygen. March 27, 2006. Available at: http://www.seniorjournal. com/news/medicare/6-03-27-medicareexpands.htm. Accessed May 16, 2006.
141. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388-391.
142. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care. 2006;29(suppl 1):S4-S42.
143. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458-1465.
144. Lenfant C. JNC guidelines: is the message getting through? JAMA. 1997;278:1778-1779.
145. Maviglia SM, Teich JM, Fiskio J, Bates DW. Using an electronic medical record to identify opportunities to improve compliance with cholesterol guidelines. J Gen Intern Med. 2001;16:531-537.
146. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87:819-822.
147. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2, and 3. J Am Coll Cardiol. 2000;36:2056-2063.
148. Cabana MD, Kim C. Physician adherence to preventive cardiology guidelines for women. Women's Health Issues. 2003;13:142-149.
149. Brindis RG, Sennett C. Physician adherence to clinical practice guidelines: does it really matter? Am Heart J. 2003;45:13-15.
150. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: the guidelines applied in practice (GAP) initiative. JAMA. 2002;287:1269-1276.
151. Zheng ZJ, Croft JB, Giles WH, et al. State-specific mortality from sudden cardiac death-United States, 1999. MMWR Morb Mortal Wkly Rep. 2002;51:123-126.
152. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P, for the CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-187.
153. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
154. Agency for Healthcare Research and Quality. The Guide to Cinical Preventive Services 2005: Recommendations of the US Preventive Services Task Force. Available at: http://www.ahrq.gov/clinic/pocketgd.pdf. Accessed October 4, 2006.
155. Naghavi M, Falk E, Hecht HS, et al. From vulnerable plaque to vulnerable patient-part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006;98(suppl):2H-15H.
156. Lloyd-Jones DM, Larson MF, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068-3072.
157. Young JB. The global epidemiology of heart failure. Med Clin North Am. 2004;88:1135-1143.